About AHEAD Medicine
AHEAD Medicine develops an artificial intelligence (AI) based flow cytometry analysis platform. The company enables a reduction of exam turnaround time and timely access to life-saving therapies. AHEAD-flow uses artificial intelligence to automatically analyze the immunophenotype of specimens and detect abnormalities in clinical flow cytometry data. It was founded in 2020 and is based in Berkeley, California.
Expert Collections containing AHEAD Medicine
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AHEAD Medicine is included in 1 Expert Collection, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Latest AHEAD Medicine News
Jan 11, 2024
News provided by Share this article Share toX SAN JOSE, Calif., Jan. 11, 2024 /PRNewswire/ -- AI HealthTech startup AHEAD Medicine Corporation is delighted to announce its poster presentation at the esteemed American Society of Hematology (ASH) 2023 Conference. The presentation marks a pivotal achievement in the development of AHEAD's proprietary cyto-copilot technology, which automates the analysis of diagnostic flow cytometry data across various reagent and instrument platforms for disease screening and classification such as distinguishing acute myeloid leukemia from non-neoplastic samples. Titled "Machine learning-facilitated cross-panel automatic classification at both sample and cell level in acute myeloid leukemia", the poster unveiled AHEAD's continuous efforts in developing automatic analysis solutions for flow cytometry data derived from disparate panels and instruments. AHEAD's cyto-copilot, a machine learning-driven platform, was developed to deliver universally applicable, efficient, and reproducible automated flow cytometry data analysis, independent of the flow cytometry panel or instrument used. The study presented at ASH 2023 focused on the integration of diagnostic data measured using both BD Biosciences and Beckman Coulter panels. These two systems are among the most widely used in clinical and research settings but have traditionally required separate analysis due to differences in available markers and instrument settings. AHEAD's panel-agnostic methodology fosters a more inclusive and adaptable automated analysis of flow cytometry data, an essential advancement given the growing and rapidly evolving demands for flow cytometry testing globally. AHEAD Medicine's dedication to enhancing healthcare access through innovative data analysis in healthcare is reflective of its ongoing mission to devise solutions that navigate the intricacies of contemporary medicine. For further details about AHEAD Medicine and to view the poster at ASH 2023, please visit https://www.aheadmedicine.com/publications/2023ash About AHEAD Medicine Corporation AHEAD Medicine Corporation stands at the forefront of AI HealthTech innovation, specializing in advanced data analytics for disease diagnosis, post-treatment monitoring, biomedical research, and quality assurance in cell therapy manufacturing. SOURCE AHEAD Medicine Corporation PRN Top Stories Newsletters Enter Your Email By signing up you agree to receive content from us. Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice . You can withdraw your consent at any time in the footer of every email you'll receive.Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten. Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice . Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen.En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part. Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice . Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu.Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN . Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.
AHEAD Medicine Frequently Asked Questions (FAQ)
When was AHEAD Medicine founded?
AHEAD Medicine was founded in 2020.
Where is AHEAD Medicine's headquarters?
AHEAD Medicine's headquarters is located at 2150 Shattuck Ave Penthouse, Berkeley.
What is AHEAD Medicine's latest funding round?
AHEAD Medicine's latest funding round is Convertible Note.
How much did AHEAD Medicine raise?
AHEAD Medicine raised a total of $110K.
Who are the investors of AHEAD Medicine?
Investors of AHEAD Medicine include Berkeley SkyDeck.